Icure Pharmaceutical Incorporation (KOSDAQ:175250)
South Korea · Delayed Price · Currency is KRW 2,170.00
+231.00 (11.91%)
At close: Aug 5, 2025
KOSDAQ:175250 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | - | - | - | -0 | - | 0 |
| 93,445 | 83,385 | 50,705 | 56,806 | 59,367 | 64,283 | |
Revenue Growth (YoY) | 64.23% | 64.45% | -10.74% | -4.31% | -7.65% | -28.69% |
Cost of Revenue | 88,994 | 78,987 | 44,064 | 55,508 | 64,947 | 69,086 |
Gross Profit | 4,451 | 4,398 | 6,641 | 1,298 | -5,580 | -4,804 |
Selling, General & Admin | 7,434 | 9,184 | 15,499 | 15,114 | 11,826 | 16,425 |
Research & Development | 2,839 | 2,932 | 2,568 | 3,685 | 4,242 | 2,419 |
Amortization of Goodwill & Intangibles | 581.74 | 786.77 | 1,312 | 1,895 | 1,358 | 829.82 |
Other Operating Expenses | 315.5 | 321.98 | 455 | 486.93 | 522.68 | 394.27 |
Operating Expenses | 20,132 | 22,731 | 22,610 | 28,903 | 21,507 | 25,316 |
Operating Income | -15,681 | -18,333 | -15,969 | -27,605 | -27,087 | -30,119 |
Interest Expense | -2,873 | -3,418 | -4,126 | -5,689 | -7,279 | -5,420 |
Interest & Investment Income | 240.51 | 301.73 | 328.46 | 813.4 | 1,309 | 949.41 |
Currency Exchange Gain (Loss) | -168.49 | -153.68 | -18.48 | 36.21 | -6.69 | 98.32 |
Other Non Operating Income (Expenses) | -731.61 | -406.1 | 745.3 | 1,587 | -4,377 | 2,214 |
EBT Excluding Unusual Items | -19,214 | -22,010 | -19,039 | -30,858 | -37,441 | -32,278 |
Gain (Loss) on Sale of Investments | -1,920 | -886.83 | -1,456 | 660.36 | -4,287 | -3,388 |
Gain (Loss) on Sale of Assets | 17.76 | 27.31 | 31,657 | 51.52 | -70.11 | 490.69 |
Asset Writedown | -12,773 | -12,773 | -7,533 | - | -1,292 | -3,040 |
Other Unusual Items | 389.92 | 333.92 | -134.18 | -2,231 | - | -619.46 |
Pretax Income | -33,499 | -35,308 | 3,495 | -32,377 | -43,090 | -38,835 |
Income Tax Expense | 2.48 | 5.61 | -15.54 | -226.49 | -541.28 | -450.58 |
Earnings From Continuing Operations | -33,501 | -35,314 | 3,511 | -32,151 | -42,549 | -38,384 |
Earnings From Discontinued Operations | 798.79 | 798.79 | -3,337 | - | - | - |
Net Income to Company | -32,703 | -34,515 | 173.12 | -32,151 | -42,549 | -38,384 |
Minority Interest in Earnings | 834.02 | 915.15 | 1,025 | 878.84 | 782.11 | 217.51 |
Net Income | -31,869 | -33,600 | 1,198 | -31,272 | -41,766 | -38,167 |
Net Income to Common | -31,869 | -33,600 | 1,198 | -31,272 | -41,766 | -38,167 |
Shares Outstanding (Basic) | 37 | 37 | 37 | 38 | 23 | 22 |
Shares Outstanding (Diluted) | 37 | 37 | 37 | 38 | 23 | 22 |
Shares Change (YoY) | -0.21% | 0.04% | -0.35% | 61.23% | 7.58% | 9.71% |
EPS (Basic) | -853.68 | -897.45 | 32.00 | -832.62 | -1792.96 | -1762.57 |
EPS (Diluted) | -853.68 | -897.45 | 32.00 | -837.00 | -1793.00 | -1763.00 |
Free Cash Flow | -7,359 | -7,795 | -19,077 | -15,744 | -15,479 | -31,929 |
Free Cash Flow Per Share | -197.13 | -208.19 | -509.73 | -419.20 | -664.50 | -1474.52 |
Gross Margin | 4.76% | 5.27% | 13.10% | 2.28% | -9.40% | -7.47% |
Operating Margin | -16.78% | -21.99% | -31.49% | -48.59% | -45.63% | -46.85% |
Profit Margin | -34.10% | -40.29% | 2.36% | -55.05% | -70.35% | -59.37% |
Free Cash Flow Margin | -7.88% | -9.35% | -37.62% | -27.72% | -26.07% | -49.67% |
EBITDA | -9,644 | -11,554 | -7,182 | -18,562 | -18,872 | -22,341 |
EBITDA Margin | -10.32% | -13.86% | -14.16% | -32.67% | -31.79% | -34.75% |
D&A For EBITDA | 6,038 | 6,779 | 8,786 | 9,043 | 8,216 | 7,778 |
EBIT | -15,681 | -18,333 | -15,969 | -27,605 | -27,087 | -30,119 |
EBIT Margin | -16.78% | -21.99% | -31.49% | -48.59% | -45.63% | -46.85% |
Advertising Expenses | - | 2.59 | 26.32 | 123.77 | 138.03 | 1,266 |